Skip to content

Research for the mechanism of drug-drug interaction between Panax notoginseng saponins and aspirin based on the esterase enzyme and Intestinal flora

Research for the mechanism of drug-drug interaction between Panax notoginseng saponins and aspirin based on the esterase enzyme and Intestinal flora

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000002902
Enrollment
Unknown
Registered
2020-01-05
Start date
2020-02-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Sponsors

Beijing University of Chinese Medicine, Dongzhimen hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 45-75 years; 2. meet the diagnostic criteria of CHD; 3. meet the diagnostic criteria of grade I–II angina according to the Canadian Cardiovascular Society (CCS); 4. meet the diagnostic criteria of blood stasis; 5. meet the diagnostic criteria of stable angina pectoris; 6. take regular aspirin for at least one month; 7. be informed of the study and voluntarily sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. mental or physical disorders; 2. pregnant, breast-feeding, and menstruating women, as well as women planning pregnancy within three months; 3. severe heart disease(acute myocardial infarction or acute myocardial infarction in six months), severe cardiopulmonary dysfunction (e.g. cardiac function II); 4. severe primary diseases, such as liver and renal hematopoietic system damage, liver function (ALT>=2 ULN, AST>=2 ULN, kidney function, Cr> 1.0 ULN), or nervous and mental disorder; 5. poorly controlled hypertension (systolic pressure >160 mmHg; or diastolic pressure>100mmHg); 6. having participated in clinical trials in the last three months; 7. underwent surgery or had hemorrhagic tendency in the last eight weeks; 8. drug allergy history or with allergic constitution; 9. diabetes; 10. poor compliance or unsuitability for this clinical trial by investigators judgment.

Design outcomes

Primary

MeasureTime frame
Paraoxonase;intestinal flora;Carboxylesterase;Butyrylcholinesterase;

Secondary

MeasureTime frame
P2Y12 acceptor;P-selection;PAC-1;

Countries

China

Contacts

Public ContactBaochen Zhu
zbcbock123@sina.com+86 17710790716

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026